Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HRA Pharma names new CEO
HRA Pharma’s previous CEO and founder, Andre Ulmann, will assume the role of chairman of the company’s supervisory board. Dr Gainer joined HRA Pharma in 2000 and has
HRA Pharma’s previous CEO and founder, Andre Ulmann, will assume the role of chairman of the company’s supervisory board. Dr Gainer joined HRA Pharma in 2000 and has
In this role, Mr Wilson will have overall leadership responsibility for the strategy and operations for all of the company’s finance and control functions. He will assume his
Mr Teasdale has been with Smith & Nephew for 20 years and has experience in driving top line growth and expanding margins, the company said. Most recently, he
Netherlands-based biopharmaceutical company Crucell and the Aeras Global TB Vaccine Foundation have initiated a Phase I clinical trial in infants of the jointly developed tuberculosis vaccine candidate, AERAS-402/Crucell
The companies plan to initiate a Phase III program evaluating the efficacy and safety of VEGF Trap-Eye in the treatment of central retinal vein occlusion (CRVO) in the
Austrian biotechnology company ProtAffin has completed a $18.4m series B financing round. The equity financing was co-led by Atlas Venture and SR One, the corporate venture fund of
For the first quarter of 2009, Hospira reported diluted earnings per share of $1.03, an increase of 151.2%, compared to $0.41 for the first quarter of 2008. The
The company reported total revenues of $691.5 million for the quarter ended March 31, 2009, a decrease of 5.3%, compared to $730.5 million for the quarter ended March
Dendreon, a biotechnology company, has reported promising preclinical data demonstrating the potential of D-3263, the company’s orally bioavailable small molecule, which targets TRPM8, to treat benign prostatic hyperplasia.
For the first quarter of 2009, GAAP income from operations was $5.2 million, compared to $4.4 million in the first quarter of 2008. The company reported total revenues